Find Perfluorohexyloctane manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 133331-77-8, 1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluorotetradecane, Perfluorohexyloctane, 7vyx4elwqm, Perfluorohexyloctane [who-dd], 1,1,1,2,2,3,3,4,4,5,5,6,6,-tridecafluorotetradecane
Molecular Formula
C14H17F13
Molecular Weight
432.26  g/mol
InChI Key
WRYIIOKOQSICTB-UHFFFAOYSA-N
FDA UNII
7VYX4ELWQM

Perfluorohexyloctane
1 2D Structure

Perfluorohexyloctane

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluorotetradecane
2.1.2 InChI
InChI=1S/C14H17F13/c1-2-3-4-5-6-7-8-9(15,16)10(17,18)11(19,20)12(21,22)13(23,24)14(25,26)27/h2-8H2,1H3
2.1.3 InChI Key
WRYIIOKOQSICTB-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CCCCCCCCC(C(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F
2.2 Other Identifiers
2.2.1 UNII
7VYX4ELWQM
2.3 Synonyms
2.3.1 MeSH Synonyms

1. F6h8 Cpd

2. Perfluorhexyl-octan

3. Perfluorohexyl-octan

4. Perfluorohexyloctane

2.3.2 Depositor-Supplied Synonyms

1. 133331-77-8

2. 1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluorotetradecane

3. Perfluorohexyloctane

4. 7vyx4elwqm

5. Perfluorohexyloctane [who-dd]

6. 1,1,1,2,2,3,3,4,4,5,5,6,6,-tridecafluorotetradecane

7. 1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluorotetradecane F 6h8

8. Tetradecane, 1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluoro-

9. Starbld0000620

10. Unii-7vyx4elwqm

11. 1-(tridecafluorohexyl)octane

12. Schembl890448

13. Dtxsid20440585

14. Mfcd07784188

15. Akos015911101

16. Zinc100046937

17. Bs-20913

18. Cs-0205555

19. A806597

20. J-006351

2.4 Create Date
2006-10-25
3 Chemical and Physical Properties
Molecular Weight 432.26 g/mol
Molecular Formula C14H17F13
XLogP38.7
Hydrogen Bond Donor Count0
Hydrogen Bond Acceptor Count13
Rotatable Bond Count11
Exact Mass432.1122666 g/mol
Monoisotopic Mass432.1122666 g/mol
Topological Polar Surface Area0 Ų
Heavy Atom Count27
Formal Charge0
Complexity464
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

API SUPPLIERS

read-more
read-more

01

Metrochem API Private Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Metrochem

02

Dr. Reddy\'s Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Dr Reddy Company Banner

03

Viwit Pharmaceuticals Limited

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BioProcess International
Not Confirmed
arrow

Viwit Pharmaceuticals Limited

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BioProcess International
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content

Perfluorohexyloctane

About the Company :

Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product ...

Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product groups and has been approved by ISO 9001-2015, USFDA, WHO GMP, Cofepris & Japanese authorities. Metrochem’s in-depth industry knowledge, & hi-tech & advanced infrastructure, helps it provide quality products to its customers. Note: None of the products will be supplied to the countries where this could conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer
Metrochem

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content

Perfluorohexyloctane

About the Company : Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfoli...

Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfolio that provides high-quality, low-cost APIs to leading pharma companies in 80+ countries. It has 8 USFDA-inspected facilities – 6 in India & 1 each in Mexico & the UK & are inspected by international regulatory authorities on a regular basis. Its facilities are supplemented by formulation facilities that provide a wide range of dosage forms. Product(s) under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act and not for commercial sale.
Dr Reddy Company Banner
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

MIEBO (perfluorohexyloctane ophthalmic solution) is used for the treatment of the signs and symptoms of dry eye disease (DED). MIEBO is the first and only prescription eye drop approved for DED that directly targets tear evaporation.


Lead Product(s): Perfluorohexyloctane

Therapeutic Area: Ophthalmology Brand Name: Miebo

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 12, 2023

blank

01

BioProcess International
Not Confirmed
BioProcess International
Not Confirmed

Details : MIEBO (perfluorohexyloctane ophthalmic solution) is used for the treatment of the signs and symptoms of dry eye disease (DED). MIEBO is the first and only prescription eye drop approved for DED that directly ta...

Brand Name : Miebo

Molecule Type : Small molecule

Upfront Cash : Not Applicable

September 12, 2023

blank

Details:

Under the agreement, Senju acquires Japan rights to develop, manufacture, and commercialize NOV03 (perfluorohexyloctane ophthalmic solution), the first and only prescription treatment for signs and symptoms of dry eye disease that directly targets tear evaporation.


Lead Product(s): Perfluorohexyloctane

Therapeutic Area: Ophthalmology Brand Name: NOV'03

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: SENJU PHARMACEUTICAL CO LTD

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement June 13, 2023

blank

02

Novaliq

Germany
arrow
BioProcess International
Not Confirmed

Novaliq

Germany
arrow
BioProcess International
Not Confirmed

Details : Under the agreement, Senju acquires Japan rights to develop, manufacture, and commercialize NOV03 (perfluorohexyloctane ophthalmic solution), the first and only prescription treatment for signs and symptoms of ...

Brand Name : NOV'03

Molecule Type : Small molecule

Upfront Cash : Undisclosed

June 13, 2023

blank

Details:

Miebo (perfluorohexyloctane) is the first drug approved by USFDA to treat dry eye disease associated with Meibomian gland dysfunction. It stabilizes the lipid layer for hours to protect the tear film and has the ability to penetrate the Meibomian glands.


Lead Product(s): Perfluorohexyloctane

Therapeutic Area: Ophthalmology Brand Name: Miebo

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Novaliq

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 18, 2023

blank

03

BioProcess International
Not Confirmed
BioProcess International
Not Confirmed

Details : Miebo (perfluorohexyloctane) is the first drug approved by USFDA to treat dry eye disease associated with Meibomian gland dysfunction. It stabilizes the lipid layer for hours to protect the tear film and has th...

Brand Name : Miebo

Molecule Type : Small molecule

Upfront Cash : Not Applicable

May 18, 2023

blank

Details:

NOV03 (Perfluorohexyloctane) is the first drug developed to treat dry eye disease associated with Meibomian gland dysfunction in a highly effective way. It stabilizes the lipid layer for hours to protect the tear film and has the ability to penetrate the Meibomian glands.


Lead Product(s): Perfluorohexyloctane

Therapeutic Area: Ophthalmology Brand Name: 37926

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Novaliq

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 04, 2023

blank

04

BioProcess International
Not Confirmed
BioProcess International
Not Confirmed

Details : NOV03 (Perfluorohexyloctane) is the first drug developed to treat dry eye disease associated with Meibomian gland dysfunction in a highly effective way. It stabilizes the lipid layer for hours to protect the te...

Brand Name : 37926

Molecule Type : Small molecule

Upfront Cash : Not Applicable

January 04, 2023

blank

Details:

NOV03 (perfluorohexyloctane) A potential first-in-class eye drop with a novel mechanism of action, NOV03 is an investigational therapy to treat the signs and symptoms of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD).


Lead Product(s): Perfluorohexyloctane

Therapeutic Area: Ophthalmology Brand Name: 37926

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Novaliq

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 06, 2022

blank

05

BioProcess International
Not Confirmed
BioProcess International
Not Confirmed

Details : NOV03 (perfluorohexyloctane) A potential first-in-class eye drop with a novel mechanism of action, NOV03 is an investigational therapy to treat the signs and symptoms of dry eye disease (DED) associated with Me...

Brand Name : 37926

Molecule Type : Small molecule

Upfront Cash : Not Applicable

September 06, 2022

blank

Details:

NOV03 (perfluorohexyloctane) Ophthalmic Soluton, is an investigational, proprietary, water-free, single-component preservative-free eye drop , an investigational treatment with a proposed indication of treating the signs and symptoms of dry eye disease.


Lead Product(s): Perfluorohexyloctane

Therapeutic Area: Ophthalmology Brand Name: 37926

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Novaliq

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 07, 2022

blank

06

BioProcess International
Not Confirmed
BioProcess International
Not Confirmed

Details : NOV03 (perfluorohexyloctane) Ophthalmic Soluton, is an investigational, proprietary, water-free, single-component preservative-free eye drop , an investigational treatment with a proposed indication of treating...

Brand Name : 37926

Molecule Type : Small molecule

Upfront Cash : Not Applicable

July 07, 2022

blank

Details:

NOV03 (perfluorohexyloctane) is being investigated as a first-in-class treatment with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD).


Lead Product(s): Perfluorohexyloctane

Therapeutic Area: Ophthalmology Brand Name: 37926

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 03, 2022

blank

07

BioProcess International
Not Confirmed
BioProcess International
Not Confirmed

Details : NOV03 (perfluorohexyloctane) is being investigated as a first-in-class treatment with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with Meibomian gland dysfunc...

Brand Name : 37926

Molecule Type : Small molecule

Upfront Cash : Not Applicable

May 03, 2022

blank

Details:

Presentations include results from Phase 3 trials of investigational NOV03 (perfluorohexyloctane), as well as from several studies involving products from company's consumer health care, pharmaceutical and surgical portfolios, such as XIPERE for suprachoroidal use.


Lead Product(s): Perfluorohexyloctane

Therapeutic Area: Ophthalmology Brand Name: NOV03

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 28, 2022

blank

08

BioProcess International
Not Confirmed
BioProcess International
Not Confirmed

Details : Presentations include results from Phase 3 trials of investigational NOV03 (perfluorohexyloctane), as well as from several studies involving products from company's consumer health care, pharmaceutical and surg...

Brand Name : NOV03

Molecule Type : Small molecule

Upfront Cash : Not Applicable

April 28, 2022

blank

Details:

The data show that NOV03, (perfluorohexyloctane) met both primary endpoints of total Corneal Fluorescein Staining, a measure that assesses damage to the eye, and visual analogue scale dryness score at day 57.


Lead Product(s): Perfluorohexyloctane

Therapeutic Area: Ophthalmology Brand Name: NOV03

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Bausch & Lomb Incorporated

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 25, 2022

blank

09

Novaliq

Germany
arrow
BioProcess International
Not Confirmed

Novaliq

Germany
arrow
BioProcess International
Not Confirmed

Details : The data show that NOV03, (perfluorohexyloctane) met both primary endpoints of total Corneal Fluorescein Staining, a measure that assesses damage to the eye, and visual analogue scale dryness score at day 57.

Brand Name : NOV03

Molecule Type : Small molecule

Upfront Cash : Not Applicable

April 25, 2022

blank

Details:

Company provided update on phase 3 trial of SHR8058 eye drops (perfluorohexyloctane) for the treatment of dry eye disease associated with Meibomian gland dysfunction and the trial met its prespecified primary sign endpoint improvement of total corneal fluorescein staining.


Lead Product(s): Perfluorohexyloctane

Therapeutic Area: Ophthalmology Brand Name: SHR8058

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 16, 2021

blank

10

Novaliq

Germany
arrow
BioProcess International
Not Confirmed

Novaliq

Germany
arrow
BioProcess International
Not Confirmed

Details : Company provided update on phase 3 trial of SHR8058 eye drops (perfluorohexyloctane) for the treatment of dry eye disease associated with Meibomian gland dysfunction and the trial met its prespecified primary s...

Brand Name : SHR8058

Molecule Type : Small molecule

Upfront Cash : Not Applicable

December 16, 2021

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

read-more
read-more

01

AFT Pharmaceuticals

New Zealand
BioProcess International
Not Confirmed
arrow

AFT Pharmaceuticals

New Zealand
arrow
BioProcess International
Not Confirmed

perfluorohexyloctane

Brand Name : Novatears

Dosage Form :

Dosage Strength :

Packaging : 1

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

blank

02

AFT Pharmaceuticals

New Zealand
BioProcess International
Not Confirmed
arrow

AFT Pharmaceuticals

New Zealand
arrow
BioProcess International
Not Confirmed

perfluorohexyloctane

Brand Name : Novatears

Dosage Form :

Dosage Strength :

Packaging : 1

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

blank

03

BioProcess International
Not Confirmed
arrow
arrow
BioProcess International
Not Confirmed

PERFLUOROHEXYLOCTANE

Brand Name : MIEBO

Dosage Form : SOLUTION/DROPS;OPHTHALMIC

Dosage Strength : 1.338GM/ML

Packaging :

Approval Date : 2023-05-18

Application Number : 216675

Regulatory Info : RX

Registration Country : USA

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

read-more
read-more

01

BioProcess International
Not Confirmed
arrow
arrow
BioProcess International
Not Confirmed

PERFLUOROHEXYLOCTANE

Brand Name : MIEBO

Dosage Form : SOLUTION/DROPS;OPHTHALMIC

Dosage Strength : 1.338GM/ML

Approval Date : 2023-05-18

Application Number : 216675

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20240528246464/en

BUSINESSWIRE
28 May 2024

https://www.businesswire.com/news/home/20230912964741/en

BUSINESSWIRE
12 Sep 2023

https://www.businesswire.com/news/home/20230612304814/en

BUSINESSWIRE
13 Jun 2023

https://endpts.com/bausch-lomb-and-novaliq-win-approval-for-dry-eye-disease-treatment/

Nicole DeFeudis ENDPTS
19 May 2023

https://www.businesswire.com/news/home/20230322005260/en

BUSINESSWIRE
22 Mar 2023

https://www.businesswire.com/news/home/20230104005244/en

BUSINESSWIRE
04 Jan 2023

Market Place

Do you need sourcing support? Ask us

APIs

read-more
read-more
PharmaCompass
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

US Patents

read-more
read-more

01

arrow
BioProcess International
Not Confirmed
arrow
BioProcess International
Not Confirmed

PERFLUOROHEXYLOCTANE

US Patent Number : 10449164

Drug Substance Claim :

Drug Product Claim :

Application Number : 216675

Patent Use Code : U-1900

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2033-09-12

blank

02

arrow
BioProcess International
Not Confirmed
arrow
BioProcess International
Not Confirmed

PERFLUOROHEXYLOCTANE

US Patent Number : 10369117

Drug Substance Claim :

Drug Product Claim :

Application Number : 216675

Patent Use Code : U-1900

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2033-09-12

blank

03

arrow
BioProcess International
Not Confirmed
arrow
BioProcess International
Not Confirmed

PERFLUOROHEXYLOCTANE

US Patent Number : 10058615

Drug Substance Claim :

Drug Product Claim :

Application Number : 216675

Patent Use Code : U-1900

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2033-09-12

blank

04

arrow
BioProcess International
Not Confirmed
arrow
BioProcess International
Not Confirmed

PERFLUOROHEXYLOCTANE

US Patent Number : 11357738

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 216675

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2036-09-29

blank

05

arrow
BioProcess International
Not Confirmed
arrow
BioProcess International
Not Confirmed

PERFLUOROHEXYLOCTANE

US Patent Number : 10576154

Drug Substance Claim :

Drug Product Claim :

Application Number : 216675

Patent Use Code : U-1900

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2033-09-12

blank

06

arrow
BioProcess International
Not Confirmed
arrow
BioProcess International
Not Confirmed

PERFLUOROHEXYLOCTANE

US Patent Number : 10507132

Drug Substance Claim :

Drug Product Claim :

Application Number : 216675

Patent Use Code : U-1900

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2037-06-21

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty